Johnson & Johnson Stock: Buy, Sell, or Hold?
Johnson & Johnson (NYSE: JNJ) is an iconic name in healthcare, with a history that goes back to the 1800s. But in recent years it has faced some considerable challenges, namely to do with lawsuits and the legal battles it faces with respect to its talc products. And today it's a leaner company after having spun off its consumer health business.
But the market still appears concerned -- shares of Johnson & Johnson are down 8% in the past 12 months. What should investors do with the stock?
On April 16, J&J reported its latest results, which demonstrated continued growth. Revenue of $21.4 billion for the first three months of the year represented a modest 2% increase from the same period last year. When excluding the impact of foreign currency, however, the operational growth rate was nearly 4%. Being a large global business unfortunately means that foreign currency can have a considerable impact on the business' numbers.
Source Fool.com
